Literature DB >> 23403416

Risk factors for a low linezolid trough plasma concentration in acute infections.

Laura Morata1, Marta Cuesta, Jhon F Rojas, Sebastian Rodriguez, Merce Brunet, Gregori Casals, Nazareth Cobos, Cristina Hernandez, José A Martínez, Josep Mensa, Alex Soriano.   

Abstract

Linezolid is an antibiotic with time-dependent activity, and both the percentage of time that plasma concentrations exceed the MIC and the area under the concentration-time curve over 24 h in the steady state divided by the MIC (AUC24/MIC ratio) are associated with clinical response. The aim of this study was to analyze the linezolid trough plasma concentration (C(min)) and to determine factors associated with a C(min) < 2 mg/liter and other clinically relevant thresholds. Characteristics of 78 patients receiving 600 mg/12 h of linezolid with a C(min) determination at the steady state and within the first 10 days of treatment were retrospectively reviewed. Concentrations were measured using high-pressure liquid chromatography. Univariate and multivariate analysis were performed to identify risk factors of low C(min). A total of 29.5% of patients had a C(min) < 2 mg/liter. The percentage was significantly higher in patients with an estimated glomerular filtration (eGF) > 80 ml/min, in intensive care unit (ICU) patients, and in patients with an infection due to Staphylococcus aureus. The independent predictors of C(min) < 2 mg/liter were an eGF > 80 ml/min (odds ratio [OR], 10; 95% confidence interval [CI], 2.732 to 37.037; P = 0.001) and infection due to S. aureus (OR, 5.906; 95% CI, 1.651 to 21.126; P = 0.006). A linezolid C(min) of <2 mg/liter was found in 29.5% of cases, and the risk was significantly higher among those with an eGF > 80 ml/min and in infections due to S. aureus. In patients with severe sepsis, a loading dose or continuous infusion and drug monitoring could improve the pharmacodynamic parameters associated with linezolid efficacy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23403416      PMCID: PMC3623366          DOI: 10.1128/AAC.01694-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Mitochondrial toxicity associated with linezolid.

Authors:  Alex Soriano; Oscar Miró; Josep Mensa
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

2.  High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease.

Authors:  Vin-Cent Wu; Yu-Ting Wang; Cheng-Yi Wang; I-Jung Tsai; Kwan-Dun Wu; Juey-Jen Hwang; Po-Ren Hsueh
Journal:  Clin Infect Dis       Date:  2005-11-18       Impact factor: 9.079

3.  Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients.

Authors:  N Plock; C Buerger; C Joukhadar; S Kljucar; C Kloft
Journal:  Drug Metab Dispos       Date:  2007-07-16       Impact factor: 3.922

4.  Effect of severity of sepsis on tissue concentrations of linezolid.

Authors:  Christiane Thallinger; Cornelia Buerger; Nele Plock; Sascha Kljucar; Sonja Wuenscher; Robert Sauermann; Charlotte Kloft; Christian Joukhadar
Journal:  J Antimicrob Chemother       Date:  2007-11-13       Impact factor: 5.790

5.  Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials.

Authors:  Matthew E Falagas; Ilias I Siempos; Konstantinos Z Vardakas
Journal:  Lancet Infect Dis       Date:  2008-01       Impact factor: 25.071

6.  Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Pierre-François Laterre; Thierry Dugernier; Herbert Spapen; Isabelle Delattre; Xavier Wittebole; Daniel De Backer; Brice Layeux; Pierre Wallemacq; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2010-07-01       Impact factor: 9.097

7.  Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure.

Authors:  Yasuhiro Tsuji; Yoichi Hiraki; Akiko Mizoguchi; Waka Hayashi; Ryotaro Kamohara; Hidetoshi Kamimura; Yoshiharu Karube
Journal:  J Infect Chemother       Date:  2008-04-30       Impact factor: 2.211

8.  ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries.

Authors:  Ronald N Jones; Shigeru Kohno; Yasuo Ono; James E Ross; Katsunori Yanagihara
Journal:  Diagn Microbiol Infect Dis       Date:  2009-06       Impact factor: 2.803

9.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

10.  Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.

Authors:  Chiara Adembri; Stefania Fallani; Maria Iris Cassetta; Silvia Arrigucci; Alessandra Ottaviano; Patrizia Pecile; Teresita Mazzei; Raffaele De Gaudio; Andrea Novelli
Journal:  Int J Antimicrob Agents       Date:  2007-12-04       Impact factor: 5.283

View more
  19 in total

1.  Reply to "Breakthrough bacteremia by linezolid-susceptible Enterococcus faecalis under linezolid treatment in a severe polytrauma patient".

Authors:  Laura Morata; Josep Mensa; Alex Soriano
Journal:  Antimicrob Agents Chemother       Date:  2013-12       Impact factor: 5.191

2.  Breakthrough bacteremia by linezolid-susceptible Enterococcus faecalis under linezolid treatment in a severe polytrauma patient.

Authors:  Fabio Arena; Tommaso Giani; Angelo Galano; Marcello Pasculli; Valeria Peccianti; Maria Iris Cassetta; Andrea Novelli; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2013-12       Impact factor: 5.191

3.  Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety.

Authors:  Ryan L Crass; Pier Giorgio Cojutti; Manjunath P Pai; Federico Pea
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

4.  Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact.

Authors:  Alicia Galar; Maricela Valerio; Patricia Muñoz; Luis Alcalá; Xandra García-González; Almudena Burillo; María Sanjurjo; Santiago Grau; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

5.  Continuous administration of linezolid in pneumonia: what is the level of proof?

Authors:  Olivier Mimoz; Philippe Montravers; José-Artur Paiva
Journal:  Intensive Care Med       Date:  2014-11-26       Impact factor: 17.440

6.  Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill Patients.

Authors:  Max Taubert; Michael Zoller; Barbara Maier; Sebastian Frechen; Christina Scharf; Lesca-Miriam Holdt; Lorenz Frey; Michael Vogeser; Uwe Fuhr; Johannes Zander
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

7.  Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function.

Authors:  Shawn Flanagan; Edward E McKee; Debaditya Das; Paul M Tulkens; Hiromi Hosako; Jill Fiedler-Kelly; Julie Passarell; Ann Radovsky; Philippe Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

8.  Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.

Authors:  Iris K Minichmayr; André Schaeftlein; Joseph L Kuti; Markus Zeitlinger; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

Review 9.  Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Menino Osbert Cotta
Journal:  Clin Pharmacokinet       Date:  2018-04       Impact factor: 6.447

Review 10.  Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones.

Authors:  Claire Roger; Jason A Roberts; Laurent Muller
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.